Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAX-1 for persistent cancer-related pain in palliative care
ACTRN12615000987561Phase 2Not yet recruiting
- Sponsor
- Bio & Gene
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sodium arsenite in cancer pain, sponsored by Bio & Gene. Primary endpoint: Mean daily pain intensity. Planned start Oct 2016; status: not yet recruiting.
02
Drugs
sodium arsenite
03
Conditions
cancer pain
Beyond the preview
Go deeper on ACTRN12615000987561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000987561.